KNSA Stock Forecast & Price Target

Kiniksa Pharmaceuticals has demonstrated strong growth in its prescriber base, with repeat prescribers increasing to approximately 27% and the total number of unique prescribers reaching over 4,150, highlighting increasing adoption of its lead product, Arcalyst. The company also reported a significant revenue growth of 52% year-over-year in Q2 2025, with a new full-year revenue guidance raised to $625–640 million, underscoring the robust performance of its therapeutic offerings. Additionally, Kiniksa's healthy cash position of $414.1 million and anticipated positive cash flow from Arcalyst are expected to support continued investment in pipeline development, reinforcing a positive outlook for future growth.

Kiniksa Pharmaceuticals faces significant challenges indicated by a reported average 4-point decrease in NRS among symptomatic RP patients, which highlights the limited efficacy of their primary treatment candidates. Furthermore, high turnover in key positions such as CEO and CMO poses risks to both operational stability and investor confidence, potentially leading to a negative impact on share performance. Lastly, the emergence of competing products and regulatory hurdles related to pricing for biologics in the rare disease market present substantial risks that could adversely affect the company's overall valuation.